---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-060660"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T09:50:20.160027+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Beam Q3 2023: net loss $96.1M, Lilly deal up to $600M, pipeline on track

## Summary
- Net loss of $96.1M ($1.22 per share) vs $109.6M ($1.56) in Q3 2022; R&D $100M, G&A $25.4M.
- Cash and securities $1.0B as of Sep 30, 2023; expected runway into H2 2026 with Lilly proceeds.
- Lilly acquired opt-in rights to Verve's CV programs for $200M upfront + $50M equity + up to $350M milestones ($600M total).
- BEAM-101 first patient treatment by year-end 2023; initial data on multiple patients in 2024.
- BEAM-302 regulatory filing in Q1 2024; BEAM-301 IND in H1 2024; BEAM-201 initial data in 2024.

## SEC filing metadata
- accession: 0000950170-23-060660
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000095017023060660/0000950170-23-060660-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000095017023060660/beam-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-060660
- JSON: https://secwatch.observer/filing/0000950170-23-060660.json
- Plain text: https://secwatch.observer/filing/0000950170-23-060660.txt

## Key facts
- Earnings Releases
  Beam Therapeutics Inc. reported financial results for the third quarter 2023.
  - Period: the third quarter 2023
  - Result: reported results
  source text: On November 8, 2023, Beam Therapeutics Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1745999/000095017023060660/0000950170-23-060660-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.